Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

VBI Vaccines stock price, quote, forecast and news

VBIV
CA91822J1030
A2AJ0L

Price

0.02
Today +/-
-0.00
Today %
-15.52 %
P

VBI Vaccines stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the VBI Vaccines stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the VBI Vaccines stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the VBI Vaccines stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze VBI Vaccines's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

VBI Vaccines Stock Price History

DateVBI Vaccines Price
9/24/20240.02 undefined
9/23/20240.03 undefined
9/20/20240.03 undefined
9/19/20240.02 undefined
9/18/20240.02 undefined
9/17/20240.02 undefined
9/16/20240.02 undefined
9/13/20240.02 undefined
9/12/20240.02 undefined
9/11/20240.02 undefined
9/10/20240.02 undefined
9/9/20240.02 undefined
9/6/20240.02 undefined
9/5/20240.02 undefined
9/4/20240.02 undefined
9/3/20240.02 undefined
8/30/20240.02 undefined
8/29/20240.02 undefined
8/28/20240.02 undefined

VBI Vaccines Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into VBI Vaccines, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by VBI Vaccines from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects VBI Vaccines’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of VBI Vaccines. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into VBI Vaccines’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing VBI Vaccines’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on VBI Vaccines’s growth potential.

VBI Vaccines Revenue, EBIT and net profit per share

DateVBI Vaccines RevenueVBI Vaccines EBITVBI Vaccines Net Income
2026e60.02 M undefined-15.6 M undefined-6.73 M undefined
2025e34.81 M undefined-20.42 M undefined-8.19 M undefined
2024e13.1 M undefined-38.26 M undefined-35.98 M undefined
20238.68 M undefined-55.31 M undefined-93.84 M undefined
20221.08 M undefined-81.82 M undefined-113.3 M undefined
2021630,000 undefined-68.03 M undefined-69.75 M undefined
20201.06 M undefined-43.62 M undefined-46.23 M undefined
20192.22 M undefined-46.11 M undefined-54.81 M undefined
20183.36 M undefined-54.11 M undefined-63.6 M undefined
2017870,000 undefined-37.28 M undefined-39 M undefined
2016550,000 undefined-24.85 M undefined-23.21 M undefined
2015960,000 undefined-10.96 M undefined-14.76 M undefined
20140 undefined-5.14 M undefined-73.42 M undefined
20130 undefined-5.55 M undefined-4.82 M undefined
20120 undefined-7.5 M undefined-6.76 M undefined
20110 undefined-13.68 M undefined-13.22 M undefined
20100 undefined-24.22 M undefined-24.24 M undefined
20090 undefined-680,000 undefined-670,000 undefined
20080 undefined-290,000 undefined-290,000 undefined
20070 undefined-570,000 undefined-560,000 undefined
20060 undefined-370,000 undefined-210,000 undefined
20050 undefined-370,000 undefined-360,000 undefined
20040 undefined-120,000 undefined-50,000 undefined

VBI Vaccines Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0000000000000000000000321018133460
------------------------33.33-50.00--700.0062.50161.5476.47
-----------------------33.33-250.00-800.00--1,000.00-37.50---
0000000000000000000-2-3-4-1-5-8-10-10-3000
00000000000000-24-13-7-5-5-10-24-37-54-46-43-68-81-55-38-20-15
-----------------------1,800.00-2,300.00-4,300.00--8,100.00-687.50-292.31-58.82-25.00
00000000000000-24-13-6-4-73-14-23-39-63-54-46-69-113-93-35-8-6
----------------45.83-53.85-33.331,725.00-80.8264.2969.5761.54-14.29-14.8150.0063.77-17.70-62.37-77.14-25.00
0.010.010.010.010.010.010.010.020.020.020.030.040.040.050.070.160.170.170.180.4211.472.193.987.278.58.6115.57000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The VBI Vaccines Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the VBI Vaccines is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                     
000000.10.10.10.70.60.20.2220.558.248.537.739.412.532.367.759.344.2119.1121.762.623.69
0000000100100001000600600000100010010020010001000
0000000000000000000000001.441.27
0000000000000000001.30.80.80.91.12.22.66.68.5
0000000.10.200000000.100.10.61.21.91.51.510.74.64.32.78
000000.10.20.40.80.60.20.3221.158.848.637.739.514.534.370.561.847132.1130.377.636.23
0.50.50.50.50000.20.50.91.313128.6124.9124.6116.639.51.81.92.28.511.712.314.415.611.91
0000000000000000001002000000000
000000000000001.42.52.82.2000000000
00000000000000000013.259.563.358.260.862.262.158.336.5
00000000000000000008.498.32.22.32.32.11.13
0.20.10.100000000000000000.50.70.80.60.61.31.41.18
0.70.60.60.50000.20.50.91.313128.6126.3127.1119.441.715.170.575.275.875.377.480.177.450.72
0.70.60.60.500.10.20.61.31.51.51.35149.7185.1175.7157.181.229.6104.8145.7137.6122.3209.5210.415586.95
                                                     
13.512.813.312.512.413.615.517.118.619.222.118.225.8174.9231.1226.8208.8187.445.8133.3201.8246.4285403.5442.2442.3454.21
00000-0.100000000000050.658.660.963.466.475.581.690107.43
-12.8-12.3-12.9-12-12.4-13.6-15.4-16.7-17.5-17.8-20.6-16.9-20.9-26.1-46.5-51.3-51.8-109.9-70.3-105-144-207.6-262.4-308.6-378.4-489.6-582.45
000000000000000003.4-1-3.21.1-4.2-0.81.3-1.621.428.33
000000000000000000000000000
0.70.50.40.50-0.10.10.41.11.41.51.34.9148.8184.6175.515780.925.183.7119.89888.2171.7143.864.17.53
00.20.200.10.20.10.10.10.10.10.10.10.70.40.20.20.20.421.86.11.13.74.3136.43
000000000000000000009.612.112.112.216.114.86.6
0000000.10.20.20.10.10.10.10.20.30.10.102.55.60.24.21.71.412.29.211.93
000000000000000000000000000
000000000000000000001.61.114.800050.77
00.20.200.10.20.20.30.30.20.20.20.20.90.70.30.30.22.97.613.223.529.717.332.63775.74
00000000000000000001211.512.9016.328.448.90
00000000000000000004000000000
0000000000000000001.611.13.24.245.45.13.69
0000000000000000001.613.412.616.14.220.333.8543.69
00.20.200.10.20.20.30.30.20.20.20.20.90.70.30.30.24.52125.839.633.937.666.49179.42
0.70.70.60.50.10.10.30.71.41.61.71.55.1149.7185.3175.8157.381.129.6104.7145.6137.6122.1209.3210.2155.186.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of VBI Vaccines provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand VBI Vaccines's financial health and stability.

Assets

VBI Vaccines's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that VBI Vaccines must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of VBI Vaccines after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into VBI Vaccines's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014null20152016201720182019202020212022
0000000000000-24-13-6-4-73-63-14-23-39-63-54-46-69-113
000000000000000000010001112
00000000000000000000-1000000
00000000000000-1000002312-6-1015-2
000000000000015010706042451171240
000000000000000000000112123
000000000000000000000000000
0000000000000-8-14-6-5-3-2-9-18-31-45-48-47-39-73
000000000000-100-2-200000-5-3-1-2-4
000000000000-1110-2-2-10-9010-5-3-2623-4
000000000000011000-10-902000-25250
000000000000000000000000000
00000000000000000000000041220
000000000000314530060037714640124330
00000000000031453006521366743371224419
0000000000000000000210-4-3-2-6-10
000000000000000000000000000
00000000000011738-8-7-6-5121935-8-154927-59
-0.1800-0.170-0.04-0.21-0.4-0.28-0.69-0.8-0.3-2-8.49-14.21-8.68-7.23-3.030-9.6-19.11-32.02-51.52-52.38-48.05-41.91-78.04
000000000000000000000000000

VBI Vaccines stock margins

The VBI Vaccines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of VBI Vaccines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for VBI Vaccines.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the VBI Vaccines's sales revenue. A higher gross margin percentage indicates that the VBI Vaccines retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the VBI Vaccines's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the VBI Vaccines's total revenue generated. When comparing the revenue margin year over year, investors can gauge the VBI Vaccines's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the VBI Vaccines. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the VBI Vaccines's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

VBI Vaccines Margin History

VBI Vaccines Gross marginVBI Vaccines Profit marginVBI Vaccines EBIT marginVBI Vaccines Profit margin
2026e-44.06 %-26 %-11.21 %
2025e-44.06 %-58.66 %-23.53 %
2024e-44.06 %-292.02 %-274.65 %
2023-44.06 %-637.08 %-1,080.87 %
2022-943.52 %-7,575.93 %-10,490.74 %
2021-1,609.52 %-10,798.41 %-11,071.43 %
2020-765.09 %-4,115.09 %-4,361.32 %
2019-255.86 %-2,077.03 %-2,468.92 %
2018-34.23 %-1,610.42 %-1,892.86 %
2017-497.7 %-4,285.06 %-4,482.76 %
2016-567.27 %-4,518.18 %-4,220 %
2015-291.67 %-1,141.67 %-1,537.5 %
2014-44.06 %0 %0 %
2013-44.06 %0 %0 %
2012-44.06 %0 %0 %
2011-44.06 %0 %0 %
2010-44.06 %0 %0 %
2009-44.06 %0 %0 %
2008-44.06 %0 %0 %
2007-44.06 %0 %0 %
2006-44.06 %0 %0 %
2005-44.06 %0 %0 %
2004-44.06 %0 %0 %

VBI Vaccines Stock Sales Revenue, EBIT, Earnings per Share

The VBI Vaccines earnings per share therefore indicates how much revenue VBI Vaccines has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue VBI Vaccines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates VBI Vaccines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of VBI Vaccines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating VBI Vaccines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

VBI Vaccines Revenue, EBIT and net profit per share

DateVBI Vaccines Sales per ShareVBI Vaccines EBIT per shareVBI Vaccines Earnings per Share
2026e2.09 undefined0 undefined-0.23 undefined
2025e1.21 undefined0 undefined-0.29 undefined
2024e0.46 undefined0 undefined-1.25 undefined
20230.56 undefined-3.55 undefined-6.03 undefined
20220.13 undefined-9.5 undefined-13.16 undefined
20210.07 undefined-8 undefined-8.21 undefined
20200.15 undefined-6 undefined-6.36 undefined
20190.56 undefined-11.59 undefined-13.77 undefined
20181.53 undefined-24.71 undefined-29.04 undefined
20170.59 undefined-25.36 undefined-26.53 undefined
20160.55 undefined-24.85 undefined-23.21 undefined
20152.29 undefined-26.1 undefined-35.14 undefined
20140 undefined-28.56 undefined-407.89 undefined
20130 undefined-32.65 undefined-28.35 undefined
20120 undefined-44.12 undefined-39.76 undefined
20110 undefined-85.5 undefined-82.63 undefined
20100 undefined-346 undefined-346.29 undefined
20090 undefined-13.6 undefined-13.4 undefined
20080 undefined-7.25 undefined-7.25 undefined
20070 undefined-14.25 undefined-14 undefined
20060 undefined-12.33 undefined-7 undefined
20050 undefined-18.5 undefined-18 undefined
20040 undefined-6 undefined-2.5 undefined

VBI Vaccines business model

VBI Vaccines Inc is a company focused on the development and commercialization of vaccines. The company was founded in Canada in 2001 and is currently headquartered in Cambridge, Massachusetts, USA. Its business model is based on research, development, and marketing of vaccines for the prevention and treatment of infectious diseases. VBI Vaccines works closely with academic institutions, government agencies, biotech companies, and pharmaceutical companies to advance its products. The company offers a wide range of products, including prophylactic vaccines against infectious diseases such as Hepatitis B, Cytomegalovirus, Japanese encephalitis, and uncontrolled HIV infections. It is also working on the development of therapeutic vaccines against cancer. One of VBI Vaccines' key divisions is the hepatitis B vaccines, with its innovative platform called Sci-B-Vac offering higher protection and longer effectiveness than other available vaccines. VBI Vaccines has also developed a prophylactic platform called LPV™ technology (Lipid Particle Vaccine) which facilitates vaccine production by being easy to manufacture, stable, and transportable. This technology also allows for rapid development of vaccines against new infectious diseases. The company is also involved in the clinical development of therapeutic vaccines against cancer, aiming to mobilize and activate the body's immune system against cancer cells. Successful clinical studies have been conducted for therapy vaccines against glioblastomas (a type of brain tumor) and rhabdomyosarcomas (a rare tumor). Overall, VBI Vaccines has a promising research path for the development of vaccines for the prevention and treatment of infectious diseases and cancer. The company is innovative and relies on technologies that improve vaccine effectiveness and ease their production. VBI Vaccines is one of the most popular companies on Eulerpool.com.

VBI Vaccines SWOT Analysis

Strengths

1. Established expertise in developing vaccines.

2. Strong research and development capabilities.

3. High potential for creating innovative and effective vaccines.

4. Solid financial position to support ongoing projects.

Weaknesses

1. Limited product portfolio.

2. Reliance on external funding for various projects.

3. Lack of diversification in revenue sources.

4. Vulnerable to regulatory challenges and uncertainties.

Opportunities

1. Growing global demand for vaccines.

2. Increasing government initiatives for immunization programs.

3. Potential partnerships for widening product reach.

4. Emerging markets offering untapped growth opportunities.

Threats

1. Intense competition from established pharmaceutical companies.

2. Stringent regulatory requirements for vaccine development.

3. Potential emergence of alternative treatment methods.

4. Economic fluctuations impacting healthcare budgets.

VBI Vaccines Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

VBI Vaccines Revenue by Segment

Segmente202320222021202020192018
Product3.11 M USD931,000 USD262,000 USD283,000 USD--
License3.6 M USD-----
Service1.93 M USD151,000 USD369,000 USD778,000 USD--
R&D Service Revenue----1.69 M USD-
Product Revenue----536,000 USD-
License-----2.64 M USD
Product Revenue-----604,000 USD
R&D Service Revenue-----114,000 USD

VBI Vaccines Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

VBI Vaccines Revenue by Segment

DateAsiaCANADAChina / Hong KongChina Hong KongChina/Hong KongEuropeIsraelISRAELUnited States
2023---5.59 M USD-1.09 M USD-167,000 USD1.85 M USD
2022--66,000 USD--6,000 USD-315,000 USD695,000 USD
2021--306,000 USD--4,000 USD-321,000 USD-
2020--724,000 USD--53,000 USD-284,000 USD-
2019----1.64 M USD131,000 USD455,000 USD--
2018----2.67 M USD253,000 USD435,000 USD--
2017151,000 USD----194,000 USD520,000 USD--
20164,000 USD----224,000 USD320,000 USD--

VBI Vaccines Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

VBI Vaccines historical P/E ratio, EBIT, and P/S ratio.

VBI Vaccines shares outstanding

The number of shares was VBI Vaccines in 2023 — This indicates how many shares 15.572 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue VBI Vaccines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates VBI Vaccines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of VBI Vaccines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating VBI Vaccines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

VBI Vaccines Stock splits

In VBI Vaccines's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for VBI Vaccines.

VBI Vaccines latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.54 -0.73  (-35.04 %)2024 Q1
12/31/2023-0.22 -0.01  (95.54 %)2023 Q4
9/30/2023-0.14 -1.01  (-607.28 %)2023 Q3
6/30/2023-2.2 -5.05  (-129.21 %)2023 Q2
3/31/2023-1.28 -3.22  (-152.55 %)2023 Q1
12/31/2022-0.07 -0.08  (-12.04 %)2022 Q4
9/30/2022-0.08 -0.09  (-10.29 %)2022 Q3
6/30/2022-0.07 -0.18  (-152.1 %)2022 Q2
3/31/2022-0.08 -0.08  (1.96 %)2022 Q1
12/31/2021-0.07 -0.07  (6.42 %)2021 Q4
1
2
3

Eulerpool ESG Scorecard© for the VBI Vaccines stock

Eulerpool World ESG Rating (EESG©)

57/ 100

🌱 Environment

59

👫 Social

83

🏛️ Governance

30

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

VBI Vaccines list of shareholders

%
Name
Stocks
Change
Date
7.43182 % Brii Biosciences Ltd,.2,131,4472,131,4477/10/2023
4.39927 % Perceptive Advisors LLC1,261,710-119,6454/16/2024
2.18423 % Alyeska Investment Group, L.P.626,436-70,30012/31/2023
1.51395 % ARCH Venture Partners434,201-14/26/2023
0.64308 % The Vanguard Group, Inc.184,436119,91412/31/2023
0.48371 % Geode Capital Management, L.L.C.138,729012/31/2023
0.38984 % BlackRock Institutional Trust Company, N.A.111,805012/31/2023
0.30821 % Cambridge Investment Research Advisors, Inc.88,394-5,16212/31/2023
0.25261 % Citadel Advisors LLC72,44972,44912/31/2023
0.23306 % Renaissance Technologies LLC66,84239,50012/31/2023
1
2
3
4
5
...
10

VBI Vaccines Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Yifan Pharmaceutical A Stock
Yifan Pharmaceutical A
SupplierCustomer0,93-0,640,530,490,310,43
National Holdings Corporation Stock
National Holdings Corporation
SupplierCustomer0,700,24-0,42-0,64--
Syneos Health A Stock
Syneos Health A
SupplierCustomer-0,130,630,890,930,62-0,18
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer-0,270,37-0,38-0,45-0,83-0,50
1

Most common questions regarding VBI Vaccines

What values and corporate philosophy does VBI Vaccines represent?

VBI Vaccines Inc is a biopharmaceutical company dedicated to improving the prevention and treatment of infectious diseases. Its primary focus lies in developing innovative vaccines to address unmet medical needs globally. VBI Vaccines Inc stands by a strong corporate philosophy that emphasizes scientific excellence, commitment to patients and public health, and the pursuit of groundbreaking discoveries. Through extensive research and development efforts, VBI Vaccines Inc aims to provide effective and safe immunization solutions, positioning itself as a leader in the field of infectious diseases.

In which countries and regions is VBI Vaccines primarily present?

VBI Vaccines Inc is primarily present in the United States and Canada.

What significant milestones has the company VBI Vaccines achieved?

VBI Vaccines Inc, a leading biopharmaceutical company, has achieved multiple significant milestones. One notable milestone was the successful approval of its flagship hepatitis B vaccine, Sci-B-Vac®, in Israel, Europe, and other markets. Another achievement includes the advancement of its innovative pipeline, particularly the ongoing clinical trials for its polyvalent cancer immunotherapy, VBI-1901. Furthermore, the company secured strategic partnerships and collaborations with esteemed organizations, such as Brii Biosciences and the National Institutes of Health (NIH). VBI Vaccines Inc has demonstrated its commitment to revolutionizing preventative and therapeutic measures through its noteworthy accomplishments in the field of immunotherapy.

What is the history and background of the company VBI Vaccines?

VBI Vaccines Inc is a company specializing in the discovery and development of innovative vaccines for infectious diseases. Founded in 2001, VBI Vaccines Inc has built a strong reputation in the biotech industry for its expertise in designing enveloped virus-like particle (eVLP) vaccines. With a focus on infectious diseases like hepatitis B and cytomegalovirus, VBI Vaccines Inc has made significant strides in advancing its vaccine candidates through preclinical and clinical stages. The company's commitment to cutting-edge research and development, alongside strategic collaborations, positions VBI Vaccines Inc as a key player in the global fight against infectious diseases.

Who are the main competitors of VBI Vaccines in the market?

The main competitors of VBI Vaccines Inc in the market include companies such as Novavax Inc., Inovio Pharmaceuticals Inc., and Dynavax Technologies Corporation.

In which industries is VBI Vaccines primarily active?

VBI Vaccines Inc is primarily active in the biotechnology industry.

What is the business model of VBI Vaccines?

VBI Vaccines Inc. is a biopharmaceutical company specializing in the development and commercialization of vaccines for infectious diseases. Its business model focuses on leveraging advanced technology platforms to create safe and effective immunotherapies. With a robust pipeline that includes candidates for hepatitis B, cytomegalovirus, and glioblastoma, VBI Vaccines aims to address unmet medical needs in these areas. The company's expertise in vaccine design, formulation, and manufacturing allows it to efficiently develop novel immunotherapies, aiming to improve global health outcomes. VBI Vaccines Inc. strives to be a leader in the field of preventive and therapeutic vaccines, providing innovative solutions to protect and enhance the lives of individuals worldwide.

What is the P/E ratio of VBI Vaccines 2024?

The VBI Vaccines P/E ratio is -0.01.

What is the P/S ratio of VBI Vaccines 2024?

The VBI Vaccines P/S ratio is 0.03.

What is the AlleAktien quality score of VBI Vaccines?

The AlleAktien quality score for VBI Vaccines is 6/10.

What is the revenue of VBI Vaccines 2024?

The expected VBI Vaccines revenue is 13.1 M USD.

How high is the profit of VBI Vaccines 2024?

The expected VBI Vaccines profit is -35.98 M USD.

What is the business model of VBI Vaccines

VBI Vaccines Inc is an innovative biotechnology company that specializes in the development of vaccines for infectious diseases. The company operates in various sectors to expand its vaccine offering and strengthen its position in the pharmaceutical market.

What is the VBI Vaccines dividend?

VBI Vaccines pays a dividend of 0 USD distributed over payouts per year.

How often does VBI Vaccines pay dividends?

The dividend cannot currently be calculated for VBI Vaccines or the company does not pay out a dividend.

What is the VBI Vaccines ISIN?

The ISIN of VBI Vaccines is CA91822J1030.

What is the VBI Vaccines WKN?

The WKN of VBI Vaccines is A2AJ0L.

What is the VBI Vaccines ticker?

The ticker of VBI Vaccines is VBIV.

How much dividend does VBI Vaccines pay?

Over the past 12 months, VBI Vaccines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VBI Vaccines is expected to pay a dividend of 0 USD.

What is the dividend yield of VBI Vaccines?

The current dividend yield of VBI Vaccines is .

When does VBI Vaccines pay dividends?

VBI Vaccines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VBI Vaccines?

VBI Vaccines paid dividends every year for the past 0 years.

What is the dividend of VBI Vaccines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VBI Vaccines located?

VBI Vaccines is assigned to the 'Health' sector.

Wann musste ich die Aktien von VBI Vaccines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VBI Vaccines from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did VBI Vaccines pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of VBI Vaccines in the year 2023?

In the year 2023, VBI Vaccines distributed 0 USD as dividends.

In which currency does VBI Vaccines pay out the dividend?

The dividends of VBI Vaccines are distributed in USD.

All fundamentals about VBI Vaccines

Our stock analysis for VBI Vaccines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VBI Vaccines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.